HSPH1 and melanoma: We first performed shRNA-based gene silencing to examine whether targeted inhibition of SRA enhances the immunostimulatory activity of DCs following capture of the hsp110-gp100 chaperone vaccine, which has been tested in mouse melanoma model (5, 8) and patients with advanced melanoma (11).